Literature DB >> 8080451

(R)-5-fluoro-5,6-dihydrouracil: kinetics of oxidation by dihydropyrimidine dehydrogenase and hydrolysis by dihydropyrimidine aminohydrolase.

D J Porter1, J A Harrington, M R Almond, G T Lowen, T Spector.   

Abstract

The biologically active isomer of 5-fluoro-5,6-dihydrouracil [(R)-5-fluoro-5,6-dihydrouracil, R-FUH2] was synthesized to study the kinetics of its enzymatic oxidation and hydrolysis by homogeneous dihydropyrimidine dehydrogenase (DPDase) and dihydropyrimidine aminohydrolase (DPHase), respectively. DPDase catalyzed the slow oxidation of R-FUH2 at pH 8 and 37 degrees with a Km of 210 microM and a kcat of 0.026 sec-1 at a saturating concentration of NADP+. The catalytic efficiency (kcat/Km) of DPDase for R-FUH2 was 1/14th of that for 5,6-dihydrouracil (UH2). In the opposite direction, DPDase catalyzed the reduction of 5-fluorouracil (FU) with a Km of 0.70 microM and a kcat of 3 sec-1 at a saturating concentration of NADPH. Thus, DPDase catalyzed the reduction of FU 30,000-fold more efficiently than the oxidation of R-FUH2. In contrast to the slow oxidation of R-FUH2 by DPDase, R-FUH2 was hydrolyzed very efficiently by DPHase with a Km of 130 microM and a kcat of 126 sec-1. The catalytic efficiency of DPHase for the hydrolysis of R-FUH2 was approximately twice that for the hydrolysis of UH2. Because R-FUH2 is hydrolysis of R-FUH2 was approximately twice that for the hydrolysis of UH2. Because R-FUH2 is hydrolyzed considerably more efficiently than it is oxidized and because the activity of DPHase was 250- to 500-fold greater than that of DPDase in bovine and rat liver, the hydrolytic pathway should predominate in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8080451     DOI: 10.1016/0006-2952(94)90056-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  3 in total

Review 1.  Preclinical development of eniluracil: enhancing the therapeutic index and dosing convenience of 5-fluorouracil.

Authors:  M T Paff; D P Baccanari; S T Davis; S Cao; R L Tansik; Y M Rustum; T Spector
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

2.  Host and gut bacteria share metabolic pathways for anti-cancer drug metabolism.

Authors:  Peter Spanogiannopoulos; Than S Kyaw; Ben G H Guthrie; Patrick H Bradley; Joyce V Lee; Jonathan Melamed; Ysabella Noelle Amora Malig; Kathy N Lam; Daryll Gempis; Moriah Sandy; Wesley Kidder; Erin L Van Blarigan; Chloe E Atreya; Alan Venook; Roy R Gerona; Andrei Goga; Katherine S Pollard; Peter J Turnbaugh
Journal:  Nat Microbiol       Date:  2022-09-22       Impact factor: 30.964

3.  Improved chemical syntheses of 5,6-dihydro-5-fluorouracil.

Authors:  Andrew L LaFrate; John A Katzenellenbogen
Journal:  J Org Chem       Date:  2007-09-27       Impact factor: 4.354

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.